Alfa Cytology has unveiled new services on oncolytic viral therapy for pancreatic cancer research.
NEW YORK, NY, August 28, 2024 /24-7PressRelease/ — Alfa Cytology, a New York-based biotech firm, has proudly unveiled its new services for developing oncolytic viral therapy for pancreatic cancer to provide improved solutions with the advanced technology platform and systemic workflow. This includes a complete set of design, construction, assay, and manufacture, showcasing the enormous potential of oncolytic viral therapy as a new targeted therapy method in pancreatic cancer.
The pancreas is one of the most important organs in the human digestive system, helping to regulate blood sugar levels and promote nutrient absorption. If the cells in the pancreas overgrow, pancreatic cancer will inevitably occur. In recent years, facts and research have shown that the treatment of pancreatic cancer is extremely challenging. Pancreatic cancer’s ability of resistance and evasion of immunity is one of the important reasons why it is difficult to treat. Therefore, the focus of pancreatic cancer research is on how to make cancer cells more easily recognized by the immune system and enhance the immune system’s ability to fight against cancer and overcome these obstacles.
Alfa Cytology has launched oncolytic viral therapy development services to intervene in the defensive ability of cancer cells on immune mechanisms and achieve the purpose of treatment. The services provide a comprehensive oncolytic virus development process, including design, assay, and manufacturing. Carefully selected viruses, after being modified, will undergo in vivo and in vitro assays (e.g., transgene expression assay and tumor lysis assay) to ensure their usability. In addition, with excellent production technology and a strict quality supervision system, Alfa Cytology offers a variety of oncolytic viruses for preclinical trial research, such as adenovirus, poxviruses, and vaccinia viruses.
Furthermore, Alfa Cytology provides related services on pancreatic cancer therapeutic discovery & development, involving drugs, vaccines, and diagnosis. No matter which specific area it is, Alfa Cytology is committed to helping customers get a deeper understanding of pancreatic cancer, providing satisfactory customized projects according to different needs and details.
Since its establishment, Alfa Cytology has been making unremitting efforts in cancer therapy research. Particularly, to help overcome immunodeficiency accurately, Alfa Cytology has made progress in the development of cell therapies for cancer, which is expected to drive precision therapy and bring about a revolution in tradition. All in all, Alfa Cytology takes the customer’s requirements as the benchmark and high-quality scientific achievements as the goal of giving back and being a trustworthy partner in biotechnology.
About Alfa Cytology
Alfa Cytology, a CRO company based in New York, provides extensive products and services for preclinical cancer research. The research scope provided by the company includes blood cancer, breast cancer, bladder cancer, skin cancer, etc. Alfa Cytology specializes in diverse drug development services and different therapeutic methods with various molecular types for cancer and has been constantly developing and growing stronger.
—
For the original version of this press release, please visit 24-7PressRelease.com here
